Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-05-15
1999-12-14
Degen, Nancy
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 530380, 530399, 530412, 530427, A61K 3816, A61K 3817, C07K 114, C07K 14505
Patent
active
060018003
DESCRIPTION:
BRIEF SUMMARY
This invention concerns a method for the preparation of spray dried erythropoietin and the dry erythropoietin powder produced thereby.
BACKGROUND OF THE INVENTION
Erythropoietin (EPO) is a glycoprotein hormone primarly synthesized in the kidney and is the chief regulator of red blood cell production in the body. Commercially available human EPO is produced via recombinant DNA techniques and is known as recombinant human EPO (rhEPO). rhEPO has a molecular mass of approximately 36,000 Daltons, as determined by SDS-PAGE. The molecular mass of the protein backbone is 18,398 Daltons, which indicates that the entire molecule is heavily glycolsylated. The carbohydrate residues are important for in vivo biologic activity.
Maintaining proteins, such as rhEPO, in their native state in aqueous solution or in solid phase is a major challenge to those working in the field of pharmaceutical formulations. The existence of a protein in its native state depends on protein concentration, temperature and nature of solvent, ionic strength of the buffer, etc. Changes in any of these parameters can affect the stability of a protein in solution or solid phase.
Commercial preparations of rhEPO are presently sold as either dilute aqueous solutions or in a lyophilized form which is used to form a dilute aqueous solution, both of which are administered to the body by injection. The concentration of rhEPO in these preparations is very low and the rhEPO is cleared from the body fairly quickly after administration. In view of this limitation of present preparations, there is a need for concentrated preparations of rhEPO, e.g., those containing higher amounts of rhEPO, which can be used in alternate drug delivery systems. We used spray drying techniques to prepare such preparations.
The spray drying of pharmaceuticals is known in the art. For example, see Broadhead, J. et al., "The Spray Drying of Pharmaceuticals," in Drug Dev. Ind. Pharm, 18 (11 & 12), 1169-1206 (1992). In addition to small molecule pharmaceuticals, a variety of biological materials have been spray dried and these include: enzymes, sera, plasma, micro-organisms and yeasts. Spray drying is a useful technique because it can convert a liquid pharmaceutical preparation into a fine, dustless or agglomerated powder in a one-step process. The basic technique comprises the following four steps:
a) atomization of the feed solution into a spray;
b) spray-air contact;
c) drying of the spray; and
d) separation of the dried product from the drying air.
Although known in the field of pharmaceuticals, there has not been much use of spray drying for therapeutic proteins, such as rhEPO. One apparent reason for this is the concern that such proteins may be thermally degraded by the high temperatures utilized in the spray drying process. This is especially true of complex glycoproteins, such as rhEPO, which, in addition to their polypeptide backbones, also have complex branched carbohydrate portions that are required for biological activity. The availability of lyophilization as a ready alternative further steered workers in the field away from using spray drying for therapeutic proteins. However, spray drying provides certain advantages over lyophilization in that it is more economical, fast and easy to scale up. Also, spray dried powders are often more amenable to further processing than lyophilized powders.
It is usually impractical to design formulations based merely on the lyophilization of the bulk drug. This is so because many polypeptides are relatively unstable when lyophilized in low concentrations and they can adsorb to product packaging and lose activity. In order to overcome these problems, many lyophilized pharmaceutical compositions rely on the use of solid diluents, cryoprotectants or bulking agents to increase the amount of solid material present during the lyophilization process. As a result the final lyophilized material contains a small percentage (w/w) of active drug mixed with a large percentage of other solid material.
In contrast, the present invention provides
REFERENCES:
patent: 4397840 (1983-08-01), Takezawa et al.
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 4992419 (1991-02-01), Woog
patent: 5354934 (1994-10-01), Pitt et al.
Broadhead et al. Drug Dev. Ind. Pharm. 18(11-12): 1169-1206.
Corbo Diane C.
Iqbal Kurshid
Mehta Deepak B.
Degen Nancy
Ortho Pharmaceutical Corp.
Wallen III John W.
LandOfFree
Spray dried erythropoietin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spray dried erythropoietin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spray dried erythropoietin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-863409